{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:46:20Z","timestamp":1792014380944,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007494","name":"Fondation Plan Alzheimer","doi-asserted-by":"publisher","award":["BALTAZAR"],"award-info":[{"award-number":["BALTAZAR"]}],"id":[{"id":"10.13039\/501100007494","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["Proteinopathies"],"award-info":[{"award-number":["Proteinopathies"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003750","name":"Association France Alzheimer","doi-asserted-by":"publisher","award":["Baltazar"],"award-info":[{"award-number":["Baltazar"]}],"id":[{"id":"10.13039\/501100003750","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gerontop\u00f4le d\u2019\u00cele-de-France (GERONDIF) French Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41380-026-03708-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:49:20Z","timestamp":1782254960000},"page":"6390-6400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression"],"prefix":"10.1038","volume":"31","author":[{"given":"Constance","family":"Delaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Schraen-Maschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7313-0629","authenticated-orcid":false,"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Assou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Allinquant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Bombois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-562X","authenticated-orcid":false,"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"3708_CR1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a clinical-biological construct-an international working group recommendation. JAMA Neurol. 2024;81:1304\u201311.","journal-title":"JAMA Neurol"},{"key":"3708_CR2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362.","journal-title":"Alzheimer\u2019s Dement"},{"key":"3708_CR3","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama. 2015;313:1924\u201338.","journal-title":"Jama"},{"key":"3708_CR4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC. Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol. 1999;45:358\u201368.","journal-title":"Ann Neurol"},{"key":"3708_CR5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"3708_CR6","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/alz.12545","volume":"18","author":"C Delaby","year":"2022","unstructured":"Delaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, et al. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer\u2019s disease: an international overview. Alzheimers Dement. 2022;18:1868\u201379.","journal-title":"Alzheimers Dement"},{"key":"3708_CR7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347.","journal-title":"Neurology"},{"key":"3708_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00702-021-02443-8","volume":"129","author":"M Fayolle","year":"2022","unstructured":"Fayolle M, Lehmann S, Delaby C. Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice. J Neural Transm. 2022;129:133\u20139.","journal-title":"J Neural Transm"},{"key":"3708_CR9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-024-00755-3","volume":"19","author":"S Lehmann","year":"2024","unstructured":"Lehmann S, Schraen-Maschke S, Buee L, Vidal JS, Delaby C, Hirtz C, et al. Clarifying the association of CSF abeta, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease. Mol Neurodegener. 2024;19:66.","journal-title":"Mol Neurodegener"},{"key":"3708_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S, Otto M, Piehl F, Ziemssen T, et al. Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol. 2024;20:269\u201387.","journal-title":"Nat Rev Neurol"},{"key":"3708_CR11","volume":"21","author":"C Delaby","year":"2025","unstructured":"Delaby C, Ladang A, Martinez-Yriarte J, Zecca C, Logroscino G, Kortvelyessy P, et al. Clinical use and reporting of neurofilament quantification in neurological disorders: a global overview. Alzheimers Dement. 2025;21:e70343.","journal-title":"Alzheimers Dement"},{"key":"3708_CR12","doi-asserted-by":"crossref","first-page":"P870","DOI":"10.1016\/j.jalz.2015.08.063","volume":"11","author":"N Barthelemy","year":"2015","unstructured":"Barthelemy N, Hirtz C, Schraen S, Seveno M, Bateman R, Marin P, et al. Mass spectrometry follow-up of t181, s199, s202, t205, and T217 tau phosphorylation in cerebrospinal fluid from patients revealed a specific Alzheimer\u2019s disease pattern. Alzheimer\u2019s Dement. 2015;11:P870.","journal-title":"Alzheimer\u2019s Dement"},{"key":"3708_CR13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/jnnp-2024-333467","volume":"95","author":"S Lehmann","year":"2024","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Buee L, Blanc F, et al. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2024;95:1046\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3708_CR14","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis EM, Janelidze S, Cody KA, Langhough R, Du L, Chin NA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 2023;5:fcad057.","journal-title":"Brain Commun"},{"key":"3708_CR15","doi-asserted-by":"crossref","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022.","DOI":"10.1038\/s41591-022-02066-w"},{"key":"3708_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, et al. Plasma biomarker strategy for selecting patients with alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 2024;81:69\u201378.","journal-title":"JAMA Neurol"},{"key":"3708_CR17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. Jama. 2023;330:512\u201327.","journal-title":"Jama"},{"key":"3708_CR18","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14414","volume":"21","author":"T Bittner","year":"2025","unstructured":"Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, et al. Biomarker treatment effects in two phase 3 trials of gantenerumab. Alzheimers Dement. 2025;21:e14414.","journal-title":"Alzheimers Dement"},{"key":"3708_CR19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13195-020-00721-3","volume":"12","author":"A Sorensen","year":"2020","unstructured":"Sorensen A, Blazhenets G, Schiller F, Meyer PT, Frings L. Alzheimer disease Neuroimaging I. Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer\u2019s dementia: a comparison of methods. Alzheimers Res Ther. 2020;12:155.","journal-title":"Alzheimers Res Ther"},{"key":"3708_CR20","volume":"25","author":"G Lombardi","year":"2024","unstructured":"Lombardi G, Pancani S, Manca R, Mitolo M, Baiardi S, Massa F, et al. Role of blood P-tau isoforms (181, 217, 231) in predicting conversion from MCI to dementia due to Alzheimer\u2019s disease: a review and meta-analysis. Int J Mol Sci. 2024;25:12916.","journal-title":"Int J Mol Sci"},{"key":"3708_CR21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/jnnp-2022-330540","volume":"94","author":"S Lehmann","year":"2023","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Blanc F, Paquet C, et al. Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function. J Neurol Neurosurg Psychiatry. 2023;94:411\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3708_CR22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13024-024-00753-5","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng X, Lafferty TK, Sehrawat A, Chen Y, Ferreira PCL, Bellaver B, et al. Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:68.","journal-title":"Mol Neurodegener"},{"key":"3708_CR23","volume":"21","author":"X Zeng","year":"2025","unstructured":"Zeng X, Sehrawat A, Lafferty TK, Chen Y, Rawat M, Kamboh MI, et al. Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort. Alzheimers Dement. 2025;21:e14535.","journal-title":"Alzheimers Dement"},{"key":"3708_CR24","volume":"21","author":"R Durcan","year":"2025","unstructured":"Durcan R, Heslegrave A, Swann P, Goddard J, Chouliaras L, Murley AG, et al. Novel blood-based proteomic signatures across multiple neurodegenerative diseases. Alzheimers Dement. 2025;21:e70116.","journal-title":"Alzheimers Dement"},{"key":"3708_CR25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","volume":"14","author":"O Hanon","year":"2018","unstructured":"Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Treluyer JM, et al. Plasma amyloid levels within the Alzheimer\u2019s process and correlations with central biomarkers. Alzheimers Dement. 2018;14:858\u201368.","journal-title":"Alzheimers Dement"},{"key":"3708_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303\u20138.","journal-title":"Arch Neurol"},{"key":"3708_CR27","doi-asserted-by":"crossref","unstructured":"Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Baret-Rose C, et al. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: the BALTAZAR study. Alzheimers Dement. 2022.","DOI":"10.1002\/alz.12613"},{"key":"3708_CR28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clinbiochem.2019.05.006","volume":"72","author":"LM Shaw","year":"2019","unstructured":"Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, et al. Method comparison study of the Elecsys(R) beta-Amyloid (1-42) CSF assay versus comparator assays and LC-MS\/MS. Clin Biochem. 2019;72:7\u201314.","journal-title":"Clin Biochem"},{"key":"3708_CR29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fnagi.2018.00138","volume":"10","author":"S Lehmann","year":"2018","unstructured":"Lehmann S, Delaby C, Boursier G, Catteau C, Ginestet N, Tiers L, et al. Relevance of Abeta42\/40 ratio for detection of Alzheimer disease pathology in clinical routine: the PLMR scale. Front Aging Neurosci. 2018;10:138.","journal-title":"Front Aging Neurosci"},{"key":"3708_CR30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49\u201352.","journal-title":"Neurosci Lett"},{"key":"3708_CR31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:34.","journal-title":"Alzheimers Res Ther"},{"key":"3708_CR32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417361","volume":"24","author":"S Lehmann","year":"2023","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Blanc F, Paquet C, Allinquant B, et al. Blood neurofilament levels predict cognitive decline across the Alzheimer\u2019s disease continuum. Int J Mol Sci. 2023;24:17361.","journal-title":"Int J Mol Sci"},{"key":"3708_CR33","volume":"21","author":"RE Rea Reyes","year":"2025","unstructured":"Rea Reyes RE, Wilson RE, Langhough RE, Studer RL, Jonaitis EM, Oomens JE, et al. Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer\u2019s disease and related dementias. Alzheimers Dement. 2025;21:e70166.","journal-title":"Alzheimers Dement"},{"key":"3708_CR34","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146:1592\u2013601.","journal-title":"Brain"},{"key":"3708_CR35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13195-022-01021-8","volume":"14","author":"J Nilsson","year":"2022","unstructured":"Nilsson J, Ashton NJ, Benedet AL, Montoliu-Gaya L, Gobom J, Pascoal TA, et al. Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:78.","journal-title":"Alzheimers Res Ther"},{"key":"3708_CR36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther. 2015;7:40.","journal-title":"Alzheimers Res Ther"},{"key":"3708_CR37","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol. 2024;271:2053\u201366.","journal-title":"J Neurol"},{"key":"3708_CR38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13195-023-01201-0","volume":"15","author":"J Lantero-Rodriguez","year":"2023","unstructured":"Lantero-Rodriguez J, Vrillon A, Fernandez-Lebrero A, Ortiz-Romero P, Snellman A, Montoliu-Gaya L, et al. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. Alzheimers Res Ther. 2023;15:48.","journal-title":"Alzheimers Res Ther"},{"key":"3708_CR39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312\u201339.","journal-title":"Cell"},{"key":"3708_CR40","volume":"21","author":"X Zhong","year":"2025","unstructured":"Zhong X, Wang Q, Yang M, Lin G, Yao K, Wu Z, et al. Plasma p-tau217 and p-tau217\/Abeta1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice. Alzheimers Dement. 2025;21:e14536.","journal-title":"Alzheimers Dement"},{"key":"3708_CR41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105805","volume":"117","author":"S Lehmann","year":"2025","unstructured":"Lehmann S, Gabelle A, Duchiron M, Busto G, Morchikh M, Delaby C, et al. Comparative performance of plasma pTau181\/Abeta42, pTau217\/Abeta42 ratios, and individual measurements in detecting brain amyloidosis. EBioMedicine. 2025;117:105805.","journal-title":"EBioMedicine"},{"key":"3708_CR42","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barthelemy","year":"2024","unstructured":"Barthelemy NR, Salvado G, Schindler S, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer\u2019s disease comparable or superior to clinical CSF tests. Nat Med. 2024;30:1085\u201395.","journal-title":"Nat Med"},{"key":"3708_CR43","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72:1275\u201380.","journal-title":"JAMA Neurol"},{"key":"3708_CR44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/jnnp-2022-329124","volume":"94","author":"L Barba","year":"2022","unstructured":"Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, et al. Cerebrospinal fluid beta-synuclein as a synaptic biomarker for preclinical Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2022;94:83\u201386.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3708_CR45","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-025-03565-2","volume":"31","author":"HS Oh","year":"2025","unstructured":"Oh HS, Urey DY, Karlsson L, Zhu Z, Shen Y, Farinas A, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer\u2019s disease. Nat Med. 2025;31:1592\u2013603.","journal-title":"Nat Med"},{"key":"3708_CR46","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800105","volume":"13","author":"G Sathe","year":"2019","unstructured":"Sathe G, Na CH, Renuse S, Madugundu AK, Albert M, Moghekar A, et al. Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer\u2019s disease. Proteom Clin Appl. 2019;13:e1800105.","journal-title":"Proteom Clin Appl"},{"key":"3708_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-120","volume":"11","author":"Y Matsui","year":"2011","unstructured":"Matsui Y, Satoh K, Miyazaki T, Shirabe S, Atarashi R, Mutsukura K, et al. High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease. BMC Neurol. 2011;11:120.","journal-title":"BMC Neurol"},{"key":"3708_CR48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.410430109","volume":"43","author":"I Zerr","year":"1998","unstructured":"Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol. 1998;43:32\u201340.","journal-title":"Ann Neurol"},{"key":"3708_CR49","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/acn3.51873","volume":"10","author":"S Abu-Rumeileh","year":"2023","unstructured":"Abu-Rumeileh S, Halbgebauer S, Bentivenga GM, Barba L, Baiardi S, Mastrangelo A, et al. High diagnostic performance of plasma and cerebrospinal fluid beta-synuclein for sporadic Creutzfeldt-Jakob disease. Ann Clin Transl Neurol. 2023;10:1904\u20139.","journal-title":"Ann Clin Transl Neurol"},{"key":"3708_CR50","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lleo","year":"2019","unstructured":"Lleo A, Nunez-Llaves R, Alcolea D, Chiva C, Balateu-Panos D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Mol Cell Proteom. 2019;18:546\u201360.","journal-title":"Mol Cell Proteom"},{"key":"3708_CR51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-017-0335-x","volume":"10","author":"FH Duits","year":"2018","unstructured":"Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10:5.","journal-title":"Alzheimers Res Ther"},{"key":"3708_CR52","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373\u20139.","journal-title":"J Clin Epidemiol"},{"key":"3708_CR53","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/biology10060472","volume":"10","author":"SU Hridi","year":"2021","unstructured":"Hridi SU, Barbour M, Wilson C, Franssen AJ, Harte T, Bushell TJ, et al. Increased levels of IL-16 in the central nervous system during neuroinflammation are associated with infiltrating immune cells and resident glial cells. Biology. 2021;10:472.","journal-title":"Biology"},{"key":"3708_CR54","doi-asserted-by":"crossref","first-page":"849","DOI":"10.17219\/acem\/68846","volume":"27","author":"OM Koper","year":"2018","unstructured":"Koper OM, Kaminska J, Sawicki K, Kemona H. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. Adv Clin Exp Med. 2018;27:849\u201356.","journal-title":"Adv Clin Exp Med"},{"key":"3708_CR55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2018","unstructured":"Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer\u2019s disease. J Cell Biol. 2018;217:459\u201372.","journal-title":"J Cell Biol"},{"key":"3708_CR56","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114398","volume":"188","author":"L van Olst","year":"2022","unstructured":"van Olst L, Coenen L, Nieuwland JM, Rodriguez-Mogeda C, de Wit NM, Kamermans A, et al. Crossing borders in Alzheimer\u2019s disease: a T cell\u2019s perspective. Adv Drug Deliv Rev. 2022;188:114398.","journal-title":"Adv Drug Deliv Rev"},{"key":"3708_CR57","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s43587-023-00491-1","volume":"3","author":"SF Lau","year":"2023","unstructured":"Lau SF, Wu W, Wong HY, Ouyang L, Qiao Y, Xu J, et al. The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer\u2019s disease pathology. Nat Aging. 2023;3:1219\u201336.","journal-title":"Nat Aging"},{"key":"3708_CR58","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1212\/WNL.0000000000201479","volume":"100","author":"V Planche","year":"2023","unstructured":"Planche V, Bouteloup V, Pellegrin I, Mangin JF, Dubois B, Ousset PJ, et al. Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology. 2023;100:e473\u2013e484.","journal-title":"Neurology"},{"key":"3708_CR59","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/clinchem\/hvad103","volume":"69","author":"S Lehmann","year":"2023","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Blanc F, Paquet C, et al. Head-to-head comparison of two plasma phospho-tau assays in predicting conversion of mild cognitive impairment to dementia. Clin Chem. 2023;69:1072\u201383.","journal-title":"Clin Chem"},{"key":"3708_CR60","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/alz.12949","volume":"19","author":"S Lehmann","year":"2023","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Allinquant B, Bombois S, Gabelle A, et al. Plasma Abeta42\/Abeta40 ratio is independent of renal function. Alzheimers Dement. 2023;19:2737\u20139.","journal-title":"Alzheimers Dement"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03708-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:57:24Z","timestamp":1792011444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03708-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3708"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03708-y","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the protocol, the principles of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines, the applicable European and French regulations governing research involving human participants, including Regulation (EU) No 536\/2014 where applicable, the French Public Health Code (Articles L1121-1 et seq.), and the General Data Protection Regulation (GDPR) together with the French Data Protection Act (Loi Informatique et Libert\u00e9s). Written informed consent to participate in the study was provided by all participants. The BALTAZAR study has approval from by the Paris ethics committee under # 2010-A00335-34 (CPP Ile de France IV Saint-Louis Hospital). The protocol is registered on ClinicalTrial under number NCT01315639.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"There are no conflicts of interest related to this manuscript.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}